Vistagen announced that the U.S. Patent and Trademark Office, or USPTO, has granted a U.S. patent for Vistagen’s PH80 nasal spray for treatment of migraine. The newly issued patent will be in effect until at least 2040.
Published first on TheFly
Vistagen announced that the U.S. Patent and Trademark Office, or USPTO, has granted a U.S. patent for Vistagen’s PH80 nasal spray for treatment of migraine. The newly issued patent will be in effect until at least 2040.
Published first on TheFly